Targeted imaging and therapy of prostate cancer by radionuclide labeled small molecule inhibitors of prostate specific membrane antigen
10.3760/cma.j.issn.2095-2848.2018.01.014
- VernacularTitle:放射性核素标记前列腺特异性膜抗原小分子抑制剂靶向前列腺癌的显像与治疗
- Author:
Lixing CHEN
1
;
Sijuan ZOU
;
Xiaohua ZHU
Author Information
1. 华中科技大学同济医学院附属同济医院核医学科
- Keywords:
Prostatic neoplasms;
Antigens;
Isotope labeling;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(1):53-58
- CountryChina
- Language:Chinese
-
Abstract:
Prostate specific membrane antigen (PSMA) overexpresses in most prostate cancer (PCa) lesions and plays an important role in the early diagnosis and preoperative staging,clinical decision making,recurrence and metastasis detection as well as targeted therapy.Radionuclide (especially 68Ga and 177Lu) labeled multiple small molecule inhibitors of PSMA have been wildly used in SPECT,PET imaging on PCa,and play an important role in the treatment of metastatic castration resistant prostate cancer (mCRPC).This review summarizes the development in these fields.
